In vitro activity of AZD0914, a novel DNA gyrase inhibitor, against Chlamydia trachomatis and Chlamydia pneumoniae

Antimicrob Agents Chemother. 2014 Dec;58(12):7595-6. doi: 10.1128/AAC.03920-14. Epub 2014 Oct 6.

Abstract

The in vitro activities of AZD0914, levofloxacin, azithromycin, and doxycycline against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae were tested. For AZD0914, the MIC90s for C. trachomatis and C. pneumoniae were 0.25 μg/ml (range, 0.06 to 0.5 μg/ml) and 1 μg/ml (range, 0.25 to 1 μg/ml), respectively, and the minimal bactericidal concentrations at which 90% of the isolates were killed (MBC90s) were 0.5 μg/ml for C. trachomatis (range, 0.125 to 1 μg/ml) and 2 μg/ml for C. pneumoniae (range, 0.5 to 2 μg/ml).

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Azithromycin / pharmacology
  • Barbiturates / pharmacology*
  • Chlamydia trachomatis / drug effects*
  • Chlamydia trachomatis / enzymology
  • Chlamydia trachomatis / growth & development
  • Chlamydophila pneumoniae / drug effects*
  • Chlamydophila pneumoniae / enzymology
  • Chlamydophila pneumoniae / growth & development
  • DNA Gyrase / metabolism*
  • Doxycycline / pharmacology
  • Isoxazoles
  • Levofloxacin / pharmacology
  • Microbial Sensitivity Tests
  • Morpholines
  • Oxazolidinones
  • Spiro Compounds / pharmacology*
  • Topoisomerase II Inhibitors / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Barbiturates
  • Isoxazoles
  • Morpholines
  • Oxazolidinones
  • Spiro Compounds
  • Topoisomerase II Inhibitors
  • Levofloxacin
  • Azithromycin
  • DNA Gyrase
  • zoliflodacin
  • Doxycycline